Overcoming Obstacles in Pharmacogenomic Strategies for Antiplatelet Drugs: Are we Rapid Enough?

• Mallal S , PhillipsE, CarosiG et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6) , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Tantisira KG , Lasky-SuJ, HaradaM et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13) , 1173–1183 (2011).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts JD , WellsGA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet379(9827) , 1705–1711 (2012).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14) , 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE, McCabeCH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20) , 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L , TantryUS, MarcucciR et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12) , 919–933 (2010).
   PubMed Web of Science ®Google Scholar
• Hochholzer W , TrenkD, FrommMF et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22) , 2427–2434 (2010).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16) , 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Hulot JS , ColletJP, SilvainJ et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56(2) , 134–143 (2010).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC, Mary-KrauseM et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4) , 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Xie HG . Genetic variations of S-mephenytoin 4´-hydroxylase (CYP2C19) in the Chinese population. Life Sci.66(14) , PL175–PL181 (2000).
   PubMed Web of Science ®Google Scholar
• Wallentin L , BeckerRC, BudajA et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11) , 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19) , 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Wallentin L , JamesS, StoreyRF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749) , 1320–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Reese ES , DanielMC, BeitelsheesAL, OnukwughaE. Cost–effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy32(4) , 323–332 (2012).
   PubMed Web of Science ®Google Scholar
• Holmes MV , PerelP, ShahT, HingoraniAD, CasasJP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA306(24) , 2704–2714 (2011).
   PubMed Web of Science ®Google Scholar
• Bauer T , BoumanHJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ343 , d4588 (2011).
   PubMed Web of Science ®Google Scholar
• Trenk D , StoneGW, GawazM et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59(24) , 2159–2164 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• US FDA. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (safety announcement). www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm
   Google Scholar
• Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) (RAPID STEMI). http://clinicaltrials.gov/ct2/show/NCT01452139?term=NCT01452139&rank=1
   Google Scholar
• Thrombocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI). http://clinicaltrials.gov/ct2/show/NCT01177592?term=NCT01177592&rank=1
   Google Scholar
• Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study. http://clinicaltrials.gov/ct2/show/NCT01452152?term=NCT01452152&rank=1
   Google Scholar